Page last updated: 2024-12-05

piperonyl butoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5794
CHEMBL ID1201131
CHEBI ID32687
SCHEMBL ID5490
MeSH IDM0016887

Synonyms (155)

Synonym
nia 5273
51-03-6
ethanol butoxide
(3,4-methylenedioxy-6-propylbenzyl) (butyl) diethylene glicol ether
pyrenone 606
toluene,5-(methylenedioxy)-2-propyl-
piperonyl butoxide ,
.alpha.[2-(2-butoxyethoxy)ethoxy]-4,5-methylenedioxy-2-propyltoluene
1, 5-[[2-(2-butoxyethoxy)ethoxy]methyl]-6-propyl-
6-(propylpiperonyl)butylcarbityl ether
5-propyl-4-(2,8-trioxa-dodecyl)-1,3-benzodioxol
.alpha.-[2-(2-n-butoxyethoxy)-ethoxy]-4,5-methylenedioxy-2-propyltoluene
butyl carbitol 6-propylpiperonyl ether
fmc 5273
butylcarbityl (6-propylpiperonyl) ether
ent 14,250
butocide
nsc-8401
6-propylpiperonyl butyl diethylene glycol ether
butacide
5-[[2-(2-butoxyethoxy)ethoxy]methyl]-6-propyl-1,3-benzodioxole
3,4-methylendioxy-6-propylbenzyl-n-butyl-diaethylenglykolaether
nci-c02813
wln: t56 bo do chj g3 h1o2o2o4
nsc8401
3,4-methylenedioxy-6-propylbenzyl n-butyl diethyleneglycol ether
1,3-benzodioxole, 5-[[2-(2-butoxyethoxy)ethoxy]methyl]-6-propyl-
piperonyl butoxide in solvent
5-{[(2-{[2-(butyloxy)ethyl]oxy}ethyl)oxy]methyl}-6-propyl-1,3-benzodioxole
piperonyl butoxide [ban]
3,4-methylenedioxy-6-propylbenzyl-n-butyl-diaethylenglykolaether [german]
alpha-(2-(2-butoxyethoxy)ethoxy)-4,5-methylenedioxy-2-propyltoluene
alleviate
butoxide (synergist)
piperonyl butoxyde [iso-french]
toluene, alpha-(2-(2-butoxyethoxy)ethoxy)-4,5-(methylenedioxy)-2-propyl-
ai3-14250
piperonyl butoxide, technical
brn 0288063
5-propyl-4-(2,5,8-trioxa-dodecyl)-1,3-benzodioxol [german]
nsc 8401
caswell no. 670
butyl-carbityl (6-propylpiperonyl) ether
piperonyl butoxide [bsi:iso]
5-(2-(2-butoxyethoxy)ethoxymethyl)-6-propyl-1,3-benzodioxole
3,4-methylendioxy-6-propylbenzyl-n-butyl-diaethylenglykolaether [german]
5-((2-(2-butoxyethoxy)ethoxy)methyl)-6-propyl-1,3-benzodioxole
1,3-benzodioxole, 5-((2-(2-butoxyethoxy)ethoxy)methyl)-6-propyl-
ccris 522
einecs 200-076-7
3,4-methylenedioxy-6-propylbenzyl n-butyldiethyleneglycol ether
hsdb 1755
epa pesticide chemical code 067501
6-(propylpiperonyl)-butyl carbityl ether
2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
(butylcarbityl)(6-propylpiperonyl)ether
(3,4-methylenedioxy-6-propylbenzyl) (butyl) diethylene glycol ether
5-propyl-4-(2,5,8-trioxa-dodecyl)-1,3-benzodioxole
5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6-propyl-1,3-benzodioxole
CHEBI:32687 ,
alpha-[2-(2-butoxyethoxy)ethoxy]-4,5-(methylenedioxy)-2-propyltoluene
alpha-(2-(2-n-butoxyethoxy)-ethoxy)-4,5-methylenedioxy-2-propyltoluene
butoxide, piperonyl
NCGC00090874-01
PBO ,
piperonylbutoxide, technical grade, 90%
NCGC00090874-02
NCGC00090874-03
piperonylbutoxide
AC-11663
piperonyl butoxide technical
CHEMBL1201131
D08383
para pio (tn)
piperonyl butoxide (ban)
rid mousse (tn)
P0458
5-[2-(2-butoxyethoxy)ethoxymethyl]-6-propyl-1,3-benzodioxole
NCGC00090874-05
NCGC00090874-04
HMS3264A07
C18880
cas-51-03-6
dtxsid1021166 ,
dtxcid501166
tox21_400086
2-(2-butoxyethoxy)-1-[(6-propyl(2h-benzo[d]1,3-dioxolen-5-yl))methoxy]ethane
tox21_111034
AKOS015951348
piperonyl butoxyde
ec 200-076-7
3,4-methylenedioxy-6-propylbenzyl-n-butyl-diaethylenglykolaether
lwk91tu9ah ,
unii-lwk91tu9ah
5-propyl-4-(2,5,8-trioxa-dodecyl)-1,3-benzodioxol
4-19-00-00779 (beilstein handbook reference)
FT-0631218
piperonyl butoxide [green book]
5((2-(2-butoxyethoxy)ethoxy)methyl)-6-propyl-1,3-benzodioxole
piperonyl butoxide [orange book]
piperonyl butoxide [iarc]
piperonyl butoxide [vandf]
piperonyl butoxide [who-dd]
piperonyl butoxide component of rid mousse
piperonyl butoxide [mi]
1,3-benzodioxole, 5-((2-(2-butoxyethoxy)ethoxy)methyl)-6-propyl
piperonyl butoxide [hsdb]
rid mousse component piperonyl butoxide
piperonyl butoxide [inci]
piperonyl butoxide [mart.]
piperonyl butoxide technical [vandf]
piperonyl butoxide [iso]
S11735
S4831
CCG-213921
5-((2-(2-butoxyethoxy)ethoxy)methyl)-6-propylbenzo[d][1,3]dioxole
SCHEMBL5490
tox21_111034_1
NCGC00090874-06
CS-4826
4,5-methylenedioxy-2-propylbenzyldiethylene glycol butyl ether
5-([2-(2-butoxyethoxy)ethoxy]methyl)-6-propyl-1,3-benzodioxole #
scourge (salt/mix)
anvil 10+10 ulv (salt/mix)
pyrenon
.alpha.-(2-(2-n-butoxyethoxy)-ethoxy)-4,5-methylenedioxy-2-propyltoluene
.alpha.(2-(2-butoxyethoxy)ethoxy)-4,5-methylenedioxy-2-propyltoluene
fac 5273
anvil 2+2 ulv (salt/mix)
toluene, .alpha.-[2-(2-butoxyethoxy)ethoxy]-4,5-(methylenedioxy)-2-propyl-
Q-201588
HY-B1198
AB01563216_01
DB09350
ent-14250
us9138393, piperonyl butoxide
bdbm181115
us9144538, piperonyl butoxide
piperonylbutoxide, technical, >=90% (gc)
mfcd00005842
SR-01000944266-1
sr-01000944266
piperonylbutoxide, pestanal(r), analytical standard
piperonyl butoxide 100 microg/ml in acetonitrile
piperonyl butoxide 10 microg/ml in acetonitrile
piperonyl butoxide 10 microg/ml in cyclohexane
piperonylbutoxide, british pharmacopoeia (bp) reference standard
piperonylbutoxide, certified reference material, tracecert(r)
BCP19227
nsc 8401; nsc-8401; nsc8401; ent-14250
Q420891
AS-10480
piperonyl-butoxide
EN300-18532245
5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6-propyl-1,3-dioxaindane

Research Excerpts

Overview

Piperonyl butoxide (PBO) is a pesticide synergist used in residential, commercial, and agricultural settings. It inhibits the activity of metabolic enzymes of the cytochrome P450 family known to detoxify insecticides including pyrethroids.

ExcerptReferenceRelevance
"Piperonyl butoxide (PBO) is a pesticide synergist used in residential, commercial, and agricultural settings. "( Developmental Toxicity Assessment of Piperonyl Butoxide Exposure Targeting Sonic Hedgehog Signaling and Forebrain and Face Morphogenesis in the Mouse: An
Colopy, LJ; Doroodchi, P; Everson, JL; Fink, DM; Heyne, GW; Lipinski, RJ; Martin, AA; McLaughlin, MT; Melberg, CG; Nelson, KF; Sun, MR; Ulschmid, CM, 2019
)
2.23
"Piperonyl butoxide (PBO) is a synergist that inhibits the activity of metabolic enzymes of the cytochrome P450 family known to detoxify insecticides including pyrethroids."( Evaluation of an alpha-cypermethrin + PBO mixture long-lasting insecticidal net VEERALIN® LN against pyrethroid resistant Anopheles gambiae s.s.: an experimental hut trial in M'bé, central Côte d'Ivoire.
Alou, LPA; Camara, S; Koffi, AA; N'Guessan, R; Oumbouke, WA; Rowland, M, 2019
)
1.24
"Piperonyl butoxide (PBO) is a semisynthetic chemical present in hundreds of pesticide formulations used in agricultural, commercial, and residential settings. "( Examining the developmental toxicity of piperonyl butoxide as a Sonic hedgehog pathway inhibitor.
Beames, TG; Lipinski, RJ; Rivera-González, KS, 2021
)
2.33
"Piperonyl butoxide is a semi-synthetic synergist for natural pyrethrum and synthetic pyrethroid insecticides in phytochemicals and biocides. "( Biorational substitution of piperonyl butoxide in organic production: effectiveness of vegetable oils as synergists for pyrethrums.
Dimier-Vallet, C; Marchand, PA; Vidal, R, 2018
)
2.22
"Piperonyl butoxide (PBO) is a synergist that inhibits specific metabolic enzymes within mosquitoes and has been incorporated into pyrethroid-LLINs to form pyrethroid-PBO nets."( Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa.
Choi, L; Gleave, K; Lissenden, N; Ranson, H; Richardson, M, 2018
)
2.64
"Piperonyl butoxide (PBO) is a well-known insecticide synergist capable of interacting with phase 1 metabolic enzymes, specifically esterases and cytochrome P450s. "( The interactions of piperonyl butoxide and analogues with the metabolic enzymes FE4 and CYP6CY3 of the green peach aphid Myzus persicae (Hemiptera: Aphididae).
Bass, C; Borzatta, V; Field, L; Mazzoni, E; Moores, G; Panini, M; Tozzi, F; Zimmer, CT, 2017
)
2.22
"Piperonyl butoxide (PBO) is a pesticide synergist used with pyrethroids as a domestic insecticide, and it acts as a non-genotoxic hepatocarcinogen in rats and mice. "( Elevation of cell proliferation via generation of reactive oxygen species by piperonyl butoxide contributes to its liver tumor-promoting effects in mice.
Dewa, Y; Harada, T; Ishii, Y; Kawai, M; Kemmochi, S; Mitsumori, K; Nishimura, J; Saegusa, Y; Shibutani, M; Umemura, T, 2010
)
2.03
"Piperonyl butoxide (PBO) is a synergist of pyrethroid pesticides found in many products for structural pest control, mosquito control, and home and garden uses. "( Effect of piperonyl butoxide on permethrin toxicity in the amphipod Hyalella azteca.
Amweg, EL; Johnson, CS; Lydy, MJ; Weston, DP; You, J, 2006
)
2.18
"Piperonyl butoxide (PBO) is an insecticide synergist known to inhibit the activity of cytochrome P450 enzymes. "( Piperonyl butoxide induces the expression of cytochrome P450 and glutathione S-transferase genes in Drosophila melanogaster.
Batterham, P; Daborn, PJ; Willoughby, L, 2007
)
3.23
"Piperonyl butoxide (PBO) is a synergist used in some pyrethroid and pyrethrin pesticide products and has been used in toxicity identification evaluations (TIEs) of water samples to indicate organophosphate or pyrethroid-related toxicity. "( Whole-sediment toxicity identification evaluation tools for pyrethroid insecticides: I. Piperonyl butoxide addition.
Amweg, EL; Weston, DP, 2007
)
2
"Piperonyl butoxide (PBO) is a commonly used synergist in many pyrethroid formulations due to its ability to interfere with cytochrome P450 (CYP) monooxygenases. "( Piperonyl butoxide enhances the bioconcentration and photoinduced toxicity of fluoranthene and benzo[a]pyrene to larvae of the grass shrimp (Palaemonetes pugio).
Garner, TR; Weinstein, JE, 2008
)
3.23
"Piperonyl butoxide (PIP) is a widely used synthetic methylenedioxyphenyl insecticide synergist."( Colchicine and vinblastine prevent the piperonyl butoxide-induced increase in rat biliary output of alpha-tocopherol.
Brown, MK; Mustacich, DJ; Reed, DJ, 1996
)
1.28
"Piperonyl butoxide (PB) is a widely used pesticidal synergist which inhibits many mammalian detoxification reactions."( Potentiation of methylmercury toxicity by piperonyl butoxide.
Eaton, LR; Friedman, MA, 1978
)
1.24

Effects

Piperonyl butoxide has been used as a synergist to help increase the efficacy of certain insecticides. It has been found to act as potent inhibitor for potato spindle tuber viroid in Scopolia sinensis Hemsl plant.

ExcerptReferenceRelevance
"Piperonyl butoxide (PBO) has been used as a synergist to help increase the efficacy of certain insecticides."( Can piperonyl butoxide enhance the efficacy of pyrethroids against pyrethroid-resistant Aedes aegypti?
Bingham, G; Jamet, HP; Khoa, PT; Strode, C; Tran, L, 2011
)
1.65
"Piperonyl butoxide has been shown to reduce accumulation of cephaloridine in rabbit renal cortex; however, the mechanism responsible for this effect remains unclear. "( Effect of piperonyl butoxide on organic anion and cation transport in rabbit kidneys.
Hook, JB; Kuo, CH; Tune, BM, 1983
)
2.11
"Piperonyl butoxide has been found to act as potent inhibitor for potato spindle tuber viroid in Scopolia sinensis Hemsl plant."( Piperonyl butoxide, a potent inhibitor of potato spindle tuber viroid in Scopolia sinensis.
Michniewicz, JJ; Narang, SA; Singh, RP, 1975
)
3.14

Actions

Piperonyl butoxide (PBO) is known to enhance the toxicity of prallethrin in humans due to the resistance in its metabolic degradation.

ExcerptReferenceRelevance
"PBO (Piperonyl butoxide) is known to enhance the toxicity of prallethrin in humans due to the resistance in its metabolic degradation."( Advances and future prospects of pyrethroids: Toxicity and microbial degradation.
de Araujo Pereira, AP; Jaiswal, DK; Kuhad, RC; Mukherjee, A; Prasad, R; Sharma, M; Shukla, AC; Singh, S; Verma, JP, 2022
)
1.18
"Piperonyl butoxide tended to increase expired benzene."( Toxicity-related changes in benzene metabolism in vivo.
Mitchell, JR; Timbrell, JA, 1977
)
0.98

Treatment

Piperonyl butoxide treatment with lambda-cyhalothrin caused significant increases in tGSH GSH, Hsp70, TBARS contents, and GPx and GST activities while caspase-3 activity was decreased. The same dose of paracetamol inhibited glutathione and glucuronic acid conjugation.

ExcerptReferenceRelevance
"Piperonyl butoxide pretreatment also showed sex-related modulation."( Sex-related effects of imidacloprid modulated by piperonyl butoxide and menadione in rats. Part II: genotoxic and cytotoxic potential.
Arslan, M; Buyukleyla, M; Rencuzogullari, E; Sevgiler, Y; Yardimci, M; Yilmaz, M, 2016
)
1.41
"Piperonyl butoxide treatment with lambda-cyhalothrin caused significant increases in tGSH GSH, Hsp70, TBARS contents, and GPx and GST activities while caspase-3 activity was decreased."( Oxidative and apoptotic effects of lambda-cyhalothrin modulated by piperonyl butoxide in the liver of Oreochromis niloticus.
Piner, P; Uner, N, 2012
)
1.34
"Piperonyl butoxide pretreatment of animals administered the same dose of paracetamol inhibited glutathione and glucuronic acid conjugation."( A simple HPLC assay for urinary paracetamol metabolites and its use to characterize the C3H mouse as a model for paracetamol metabolism studies.
Adams, JF; Birkett, DJ; Miners, J,
)
0.85
"Piperonyl butoxide treatment markedly influenced the plasma PK profiles for FBZ and FBZSO(2) following OFZ administration."( Plasma achiral and chiral pharmacokinetic behaviour of intravenous oxfendazole co-administered with piperonyl butoxide in sheep.
Jones, DG; McKellar, QA; Sánchez, S; Small, J, 2002
)
1.25
"Piperonyl butoxide pretreatment markedly increased the half-life of PCA in brain, but it failed to modify consistently the effects of PCA."( Long-term reduction of brain serotonin by p-chloroamphetamine: effects of inducers and inhibitors of drug metabolism.
Sanders-Bush, E; Steranka, LR, 1978
)
0.98
"The piperonyl butoxide-treated trout had lower levels of 14C in bile and higher levels of 14C in blood and muscle than control trout."( Effect of piperonyl butoxide on disposition of di-2-ethylhexyl phthalate by rainbow trout.
Lech, JJ; Melancon, MJ; Saybolt, J, 1977
)
1.14
"Piperonyl butoxide pretreatment limited both the liver GSH depletion and the hepatic necrosis normally caused by precocene I."( Hepatotoxicity of precocene I in rats. Role of metabolic activation in vivo.
Boyd, MR; Jerina, DM; Ravindranath, V, 1987
)
0.99
"Pre-treatment with piperonyl butoxide did not synergize spiromesifen, suggesting a target-site resistance mechanism."( Resistance to spiromesifen in Trialeurodes vaporariorum is associated with a single amino acid replacement in its target enzyme acetyl-coenzyme A carboxylase.
Denholm, I; ffrench-Constant, R; Gorman, K; Karatolos, N; Nauen, R; Williamson, MS, 2012
)
0.7
"Pretreatment with piperonyl butoxide decreased the incidence of elevated BUN levels following ortho-bromophenol administration."( The role of ortho-bromophenol in the nephrotoxicity of bromobenzene in rats.
Gillette, JR; Greene, KE; Lau, SS; Monks, TJ, 1984
)
0.59
"Treatment with piperonyl butoxide (PBO) or triphenylphosphate (TPP) significantly decreased the toxicity of permethrin in the four colonies tested."( Resistance to insecticides and effect of synergists on permethrin toxicity in Pediculus capitis (Anoplura: Pediculidae) from Buenos Aires.
Mougabure Cueto, GA; Picollo, MI; Vassena, CV; Vernetti, M; Zerba, EN, 2000
)
0.65
"Pretreatment with piperonyl butoxide, an inhibitor of mixed function oxidase activity, decreased (a) salicylate-induced nephrotoxicity; (b) the covalent binding of [14C]salicylate equivalents to renal mitochondria; and (c) the formation of the 2,3- and 2,5-dihydroxybenoic acid metabolites of salicylate."( The effect of mixed function oxidase induction and inhibition on salicylate-induced nephrotoxicity in male rats.
Kocsis, JJ; Kyle, ME, 1986
)
0.59
"Pretreatment with piperonyl butoxide (PIP) decreased the renal toxicity and covalent binding of MeCCNU, and ameliorated the MeCCNU-dependent decrease in liver and kidney GSH."( In vivo studies on the relationship between hepatic metabolism and the renal toxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU).
Boyd, MR; Kramer, RA; McMenamin, MG, 1986
)
0.59
"Pretreatment with piperonyl butoxide, SKF 525-A, or alpha-naphthoflavone had no significant effect on development of lesions."( Chemical modulation of 3-methylindole toxicosis in mice: effect on bronchiolar and olfactory mucosal injury.
Flory, W; Henk, WG; Turk, MA, 1986
)
0.59

Toxicity

Piperonyl butoxide has adverse effects on developmental parameters. Although pyrethroids are considered to be of low acute toxicity, they become more toxic when combined with piperonyL butoxide or tetramethrin in certain doses.

ExcerptReferenceRelevance
" These findings indicate that in contrast to paracetamol hepatoxicity which is dependent upon the mixed function oxidase system, that nephrotoxicity of p-aminophenol is dependent upon oxidation to a toxic metabolite by some other pathway."( The nephrotoxicity of p-aminophenol. II. The effect of metabolic inhibitors and inducers.
Calder, IC; Crowe, CA; Ham, KN; Tange, JD; Woods, RA; Yong, AC, 1979
)
0.26
" In addition, pretreatment with PB (640 mg/kg) had no effect on the LD50 of DMN."( Effects of piperonyl butoxide on dimethylnitrosamine metabolism and toxicity in Swiss mice.
Friedman, MA; Sanders, V, 1976
)
0.65
" The results suggest that PB had adverse effects on reproductive, developmental and behavioural parameters of mice, with increasing effects in subsequent generations of offspring."( Reproductive and neurobehavioural effects in three-generation toxicity study of piperonyl butoxide administered to mice.
Oishi, S; Takahashi, O; Tanaka, T, 1992
)
0.51
" Although the exact sequence of its hepatotoxic factors is unproven, it seems likely that lipid peroxidation through the dysfunction of antioxidant defence factors and a toxic metabolite contribute to the formation of this liver injury."( Hepatotoxicity of diethyldithiocarbamate in rats.
Hobara, T; Ishiyama, H; Kanbe, T; Ogino, K; Shimomura, Y, 1990
)
0.28
" It was concluded that a metabolite(s) contributes to or is responsible for acute NDPS-induced nephrotoxicity and that at least 1 toxic metabolite might be of extrarenal origin."( Effect of microsomal enzyme activity modulation on N-(3,5-dichlorophenyl)succinimide-induced nephrotoxicity.
Brown, PI; Rankin, GO; Richmond, CD; Teets, VJ; Wang, RT; Yang, DJ, 1987
)
0.27
" Single-treatment, subcutaneous LD50 values for DBCP were 102 mg/kg in non-pretreated and 128 mg/kg in phenobarbital pretreated rats."( Chemical modulation of 1,2-dibromo-3-chloropropane toxicity.
Kluwe, WM,
)
0.13
" Finally, we evaluated the effect of piperonyl butoxide on the nephrotoxicity of cephaloglycin, a more toxic cephalosporin that lacks the thiophene side-ring proposed as the target of MFO activation in earlier studies with cephaloridine."( Effects of piperonyl butoxide on cephalosporin nephrotoxicity in the rabbit. An effect on cephaloridine transport.
Fravert, D; Hook, JB; Hsu, CY; Kuo, CH; Tune, BM, 1983
)
0.93
" The results with PiBx suggest that either the parent compound possesses some direct cytotoxicity or that a toxic metabolite was generated through a biotransformation pathway not inhibited by PiBx."( 3,5-Dichloroaniline toxicity in Fischer 344 rats pretreated with inhibitors and inducers of cytochrome P450.
Brown, PI; Lo, HH; Rankin, GO; Valentovic, MA, 1995
)
0.29
" Slices prepared from mice pretreated with phenobarbital (an inducer of P450) potentiated the toxic effects of MPP+."( Protection and potentiation of 1-methyl-4-phenylpyridinium-induced toxicity by cytochrome P450 inhibitors and inducer may be due to the altered uptake of the toxin.
Pai, KS; Ravindranath, V; Sriram, K, 1995
)
0.29
" The dose levels of piperonyl butoxide in the present study produced adverse effects on developmental parameters."( Developmental toxicity evaluation of piperonyl butoxide in CD-1 mice.
Fujitani, T; Oishi, S; Takahashi, O; Tanaka, T, 1994
)
0.89
" Our experiments show that CY is more toxic than PERM to adult and neonatal rats."( Acute toxicity of two pyrethroids, permethrin, and cypermethrin in neonatal and adult rats.
Cantalamessa, F, 1993
)
0.29
" PB pretreatment also enhanced some monitored renal effects of a toxic dose (0."( Effect of microsomal enzyme modulators on N-(3,5-dichlorophenyl)-2-hydroxysuccinimide (NDHS)-induced nephrotoxicity in the Fischer 344 rat.
Anestis, DK; Beers, KW; Brown, PI; Nicoll, DW; Rankin, GO, 1993
)
0.29
" With worker ants the toxic effects started with compound 5 and increased with the number of carbons in the side chain."( Toxicity of synthetic piperonyl compounds to leaf-cutting ants and their symbiotic fungus.
Bacci Júnior, M; Bueno, FC; Bueno, OC; Correa, AG; Crisóstomo, FR; da Silva, MF; Fernandes, JB; Hebling, MJ; Pagnocca, FC; Victor, SR; Vieira, PC, 2001
)
0.31
"Based on 48 h LD50 estimates from topical bioassays, cypermethrin was more toxic than permethrin to Helicoverpa zea (Boddie) larvae and adults; however, the two pyrethroids did not differ significantly in their relative toxicities to Spodoptera frugiperda (J."( Toxicity of pyrethroids and effect of synergists to larval and adult Helicoverpa zea, Spodoptera frugiperda, and Agrotis ipsilon (Lepidoptera: Noctuidae).
Knowles, CO; Usmani, KA, 2001
)
0.31
" Although not acutely toxic at low concentrations (1-20 ng/g), AFB1 had significant chronic effects, including protracted development, increased mortality, decreased pupation rate, and reduced pupal weight."( Toxicity of aflatoxin B1 to Helicoverpa zea and bioactivation by cytochrome P450 monooxygenases.
Berenbaum, MR; Niu, G; Schuler, MA; Wen, Z; Zeng, RS, 2006
)
0.33
" IPM was also well tolerated, with minimal adverse events."( North American efficacy and safety of a novel pediculicide rinse, isopropyl myristate 50% (Resultz).
Goodman, JJ; Kaul, N; Palma, KG; Silagy, SS; Toole, J,
)
0.13
"Data suggest that IPM is a safe and effective therapy for the treatment of head lice in children and adults."( North American efficacy and safety of a novel pediculicide rinse, isopropyl myristate 50% (Resultz).
Goodman, JJ; Kaul, N; Palma, KG; Silagy, SS; Toole, J,
)
0.13
" PBO alone was not particularly toxic to grass shrimp larvae."( Piperonyl butoxide enhances the bioconcentration and photoinduced toxicity of fluoranthene and benzo[a]pyrene to larvae of the grass shrimp (Palaemonetes pugio).
Garner, TR; Weinstein, JE, 2008
)
1.79
" As a result, the findings showed that although pyrethroids are considered to be of low acute toxicity, they become more toxic when combined with piperonyl butoxide or tetramethrin in certain doses."( Repeated-dose 14-day dermal toxicity of different combinations of some synthetic pyrethroid insecticides, piperonyl butoxide, and tetramethrin in rats.
Aksoy, A; Atmaca, E; Cenesiz, M; Das, YK; Gulbahar, MY; Guvenc, D; Yarim, GF; Yavuz, O, 2010
)
0.77
", fungi that produce toxic aflatoxins."( Effects of a naturally occurring and a synthetic synergist on toxicity of three insecticides and a phytochemical to navel orangeworm (Lepidoptera: Pyralidae).
Berenbaum, MR; Lawrance, A; Niu, G; Pollock, HS; Siegel, JP, 2012
)
0.38
" Immunotoxicology focuses on the evaluation of the potential adverse effects of xenobiotics on immune mechanisms that can lead to harmful changes in host responses such as: increased susceptibility to infectious diseases and tumorigenesis; the induction of hypersensitivity reactions; or an increased incidence of autoimmune disease."( Immunotoxicity in mice induced by short-term exposure to methoxychlor, parathion, or piperonyl butoxide.
Fukuyama, T; Harada, T; Hayashi, K; Kosaka, T; Miyashita, L; Nishino, R; Tajima, Y; Ueda, H; Wada, K,
)
0.36
" Four of 43 postapplication sediment samples were significantly more toxic than their corresponding pre-application samples, but none of the observed toxicity was attributed to the application events."( Monitoring the aquatic toxicity of mosquito vector control spray pesticides to freshwater receiving waters.
Anderson, BS; Denton, D; Isorena, P; Larsen, K; Phillips, BM; Siegler, K; TenBrook, P; Tjeerdema, RS; Voorhees, JP, 2014
)
0.4
"Pyrethroid insecticides are commonly used in pest control and are present at toxic concentrations in surface waters of agricultural and urban areas worldwide."( Tracking pyrethroid toxicity in surface water samples: Exposure dynamics and toxicity identification tools for laboratory tests with Hyalella azteca (Amphipoda).
Deanovic, LA; Fong, S; Hammock, BG; Stillway, M; Werner, I, 2018
)
0.48
" The most toxic EOCs were aromatic EOCs carvacrol, eugenol, and tropolone, followed by aliphatic EOC limonene; all had LD50 values of <0."( Topical Toxicity Profiles of Some Aliphatic and Aromatic Essential Oil Components Against Insecticide-Susceptible and Resistant Strains of German Cockroach (Blattodea: Ectobiidae).
Appel, AG; Hu, XP; Oladipupo, SO, 2020
)
0.56
" Related adverse developmental outcomes in humans are etiologically heterogeneous, and, while studies are limited, PBO exposure during pregnancy has been linked to neurodevelopmental deficits."( Examining the developmental toxicity of piperonyl butoxide as a Sonic hedgehog pathway inhibitor.
Beames, TG; Lipinski, RJ; Rivera-González, KS, 2021
)
0.89
" Despite previously demonstrated effects of PBO, the detailed mechanism of PBO in spermatozoa and reproductive toxic effects on male germ cells have not been fully elucidated."( Piperonyl butoxide, a synergist of pesticides can elicit male-mediated reproductive toxicity.
Bae, JW; Kwon, WS, 2021
)
2.06
" Natural pyrethrins have been used since ancient times as insect repellers, and their synthetic versions especially type 2 pyrethroids could be highly toxic to humans."( Advances and future prospects of pyrethroids: Toxicity and microbial degradation.
de Araujo Pereira, AP; Jaiswal, DK; Kuhad, RC; Mukherjee, A; Prasad, R; Sharma, M; Shukla, AC; Singh, S; Verma, JP, 2022
)
0.72
" Adverse clinical observations (urogenital wetness and staining) occurred in the 1000 mg/kg/day dose group."( Developmental and reproduction toxicity of piperonyl butoxide part 1 developmental safety of piperonyl butoxide in the CD® (Sprague Dawley) rat.
Hauswirth, JW; Hoberman, AM, 2022
)
0.98
" No maternal or fetal adverse effects were seen at the 50 mg/kg/day dose level."( Developmental and reproduction toxicity of piperonyl butoxide part 2 developmental safety of piperonyl butoxide in the NZW rabbit.
Hauswirth, JW; Hoberman, AM, 2022
)
0.98

Pharmacokinetics

ExcerptReferenceRelevance
"A pharmacokinetic model for the accumulation of di-2-ethylhexyl phthalate (DEHP) by sheepshead minnow predicted a significant increase in the bioconcentration factor (BCF) of DEHP if its metabolism were inhibited."( Metabolic inhibition and di-2-ethylhexyl phthalate pharmacokinetics in fish.
Hayton, WL; Karara, AH,
)
0.13
" A pharmacokinetic dose titration study was carried out in sheep with fenbendazole (5 mg kg-1) and piperonyl butoxide administered orally at 0, 15, 31, 63, 125 and 250 mg kg-1."( Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications.
Benchaoui, HA; McKellar, QA, 1996
)
0.78
" Achiral and chiral pharmacokinetic (PK) profiles for OFZ, after the co-administration of PB, were characterized by a significantly greater area under the concentration--time curve (AUC) and a longer mean residence time (MRT)."( Plasma achiral and chiral pharmacokinetic behaviour of intravenous oxfendazole co-administered with piperonyl butoxide in sheep.
Jones, DG; McKellar, QA; Sánchez, S; Small, J, 2002
)
0.53

Compound-Compound Interactions

ExcerptReferenceRelevance
"In a randomized controlled trial, 58 subjects were treated for Pediculus humanus var capitis with either pyrethrins combined with piperonyl butoxide (RID, Pfizer Inc, New York) or 1% permethrin (NIX, Burroughs Wellcome Co, Research Triangle Park, NC); 31 subjects received RID and 27 subjects received NIX."( Pyrethrins combined with piperonyl butoxide (RID) vs 1% permethrin (NIX) in the treatment of head lice.
Carson, DS; Tribble, PW; Weart, CW, 1988
)
0.78
"This study shows evidence of a reduced performance of pyrethroid-CFP nets when combined with pyrethroid-PBO ITNs compared to when applied alone and higher efficacy with net combinations that included pyrethroid-CFP nets."( Can the performance of pyrethroid-chlorfenapyr nets be reduced when combined with pyrethroid-piperonyl butoxide (PBO) nets?
Agbevo, A; Ahoga, J; Gbegbo, M; N'dombidjé, B; Ngufor, C; Nounagnon, J; Syme, T, 2023
)
1.13

Bioavailability

ExcerptReferenceRelevance
" Pretreatment of goats with the inhibitor caused a greater than three-fold increase in the relative bioavailability of fenbendazole and fenbendazole sulphoxide."( Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications.
Benchaoui, HA; McKellar, QA, 1996
)
0.57
" The resultant increase in bioavailability of FBZ and its metabolite oxfendazole (OFZ) has important implications for the efficacy of these drugs against benzimidazole (BZD)-resistant strains of Teladorsagia circumcincta."( Plasma achiral and chiral pharmacokinetic behaviour of intravenous oxfendazole co-administered with piperonyl butoxide in sheep.
Jones, DG; McKellar, QA; Sánchez, S; Small, J, 2002
)
0.53
" The bioconcentration of total radioactivity after 24 h exposure was 50% lower in the natural lake water, indicating decreased bioavailability of pyrene by the dissolved organic matter."( Biotransformation and bioconcentration of pyrene in Daphnia magna.
Akkanen, J; Kukkonen, JV, 2003
)
0.32
" Overall metabolic rates decreased with increasing number of substitution at 2- and 6-position of BPA structures, which may be consequences of limited bioavailability or steric hindrance to conjugate-forming reaction."( Biodegradation of bisphenol A and its halogenated analogues by Cunninghamella elegans ATCC36112.
Keum, YS; Kim, JH; Lee, HR; Park, HW, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Regulation of cytochrome P-450 isozymes by methylenedioxyphenyl compounds was studied. Levels of mRNA, protein, and enzyme activity in hepatic tissue from C57BL/6 and DBA/2 mice were measured. When exposure to diazinon occurred in the presence of increasing amounts of piperonyl butoxide (PBO), AChE inhibition decreased in a dose-response fashion.

ExcerptRelevanceReference
" Cyano-alpha-T plus PBO was more effective for reducing mosquito populations than alpha-terthienyl (alpha-T) plus PBO at comparable dosages, although it exhibited slightly lower insecticidal activity at a dosage of 20 g/ha than a formulation of Bacillus thuringiensis var."( Toxicity and residual action of the photoactivated compound, cyano-alpha-terthienyl, and its efficacy for reducing pre-imaginal populations of mosquitoes.
Arnason, JT; Dosdall, LM; Galloway, MM, 1992
)
0.28
" Litter size and litter weight were reduced in higher-dosed groups, and the body weight of the pups in the lactation period was reduced in dosed pups in each generation."( Reproductive and neurobehavioural effects in three-generation toxicity study of piperonyl butoxide administered to mice.
Oishi, S; Takahashi, O; Tanaka, T, 1992
)
0.51
" Body weight of dosed pups was reduced in the lactation period."( Effects of piperonyl butoxide on F1 generation mice.
Tanaka, T, 1992
)
0.67
" Mosquitoes treated with Scourge required more time and a higher dosage to respond in a physiological manner similar to those treated with either of the candidate adulticides."( Comparison of the synthetic pyrethroids Esbiothrin and Bioresmethrin with Scourge and Cythion against adult mosquitoes in a laboratory wind tunnel.
Boike, AH; Coughlin, JS; Floore, TG; Greer, MJ; Rathburn, CB, 1992
)
0.28
"The adulticidal effect of ULV and thermal fog malathion, Scourge and naled was tested at 2x label dosage (1."( Effects of ultra-low volume and thermal fog malathion, Scourge and naled applied against caged adult Culicoides furens and Culex quinquefasciatus in open and vegetated terrain.
Jordan, S; Linley, JR, 1992
)
0.28
" Renal glutathione was far more susceptible to the initial rapid depleting effects of ortho-bromophenol than was hepatic glutathione, the dose-response curve for hepatic glutathione depletion being shifted to the right."( The role of ortho-bromophenol in the nephrotoxicity of bromobenzene in rats.
Gillette, JR; Greene, KE; Lau, SS; Monks, TJ, 1984
)
0.27
" The rats were then given a calculated LD50 dosage (13."( Toxicologic study of carboxyatractyloside (active principle in cocklebur--Xanthium strumarium) in rats treated with enzyme inducers and inhibitors and glutathione precursor and depletor.
Clark, JD; Hatch, RC; Jain, AV; Weiss, R, 1982
)
0.26
" These changes were detectable by light or electron microscopy 24 h after dosing with hydrazine."( Studies on hydrazine hepatotoxicity. 1. Pathological findings.
Scales, MD; Timbrell, JA, 1982
)
0.26
" Piperonyl butoxide also caused essential thrombocythemia with a dose-response relationship."( Chronic toxicity studies of piperonyl butoxide in F344 rats: induction of hepatocellular carcinoma.
Fujitani, T; Oishi, S; Takahashi, O; Tanaka, T; Yoneyama, M, 1994
)
1.49
" The effect of pretreatment of rats with various inhibitors and inducers of cytochrome P450 on these dose-response relationships was investigated."( Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo.
Jenner, AM; Timbrell, JA, 1994
)
0.29
"Regulation of cytochrome P-450 isozymes 1a-1, 1a-2, and 2b-10 by methylenedioxyphenyl compounds was studied by measuring levels of mRNA, protein, and enzyme activity in hepatic tissue from C57BL/6 (Ah+) and DBA/2 (Ah-) mice dosed with isosafrole (ISO) or piperonyl butoxide (PBO)."( Regulation of cytochrome P-450 isozymes by methylenedioxyphenyl compounds.
Adams, NH; Hodgson, E; Levi, PE, 1993
)
0.47
" A higher dosage against An."( Efficacy of a 1:1 and 1:5 mixture of technical permethrin and piperonyl butoxide against Anopheles quadrimaculatus and Psorophora columbiae.
Groves, RL; Meisch, MV; Nunez, R, 1995
)
0.53
" In this study, AHR knock-out mice were dosed intraperitoneally with PBO (200 mg/kg) or ACN (100 mg/kg)."( Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
Fernandez-Salguero, P; Gonzalez, FJ; Hodgson, E; Levi, PE; Ryu, DY, 1996
)
1.74
"In this 8-hour in vitro flow-through diffusion study, porcine skin sections were dosed with 40 micrograms of CA/cm2 of surface area, different amounts of solvents (40 or 80% acetone or dimethyl sulfoxide [DMSO]), different amounts of a surfactant (0, 1, or 5% sodium lauryl sulfate [SLS]), an insect repellent (0 or 15% diethyl-m-toluamide [DEET]), an insecticide synergist (0 or 2% piperonyl butoxide [PB]), and a CA metabolite (40 micrograms/cm2 1-naphthol [1-NA])."( Influence of inert ingredients in pesticide formulations on dermal absorption of carbaryl.
Baynes, RE; Riviere, JE, 1998
)
0.47
" Irrespective of the solvent, increasing water content in pesticide dosing mixtures significantly increased CA absorption from SLS mixtures only."( Influence of inert ingredients in pesticide formulations on dermal absorption of carbaryl.
Baynes, RE; Riviere, JE, 1998
)
0.3
" Dose-response curves to ACh were constructed in air- or O(3)-exposed rabbits."( Interactions between cytochrome P-450 activities and ozone-induced modulatory effects on endothelial permeability in rabbit lungs: influence of gender.
Delaunois, A; Florquin, S; Gustin, P; Montano, LM; Segura, P; Vargas, MH, 1999
)
0.3
" Each formulation was tested at 50, 67, and 100% of respective maximum label dosage rates."( Field trial efficacy of Anvil 10+10 and Biomist 31:66 against Ochlerotatus sollicitans in Delaware.
Lesser, CR, 2002
)
0.31
"Fifteen naturally parasitised crossbred male ponies were allocated into 3 groups (n = 5) and treated orally as follows: Group I (control) received distilled water as placebo; Group II was dosed with OFZ (10 mg/kg bwt); and Group III was treated with OFZ (10 mg/kg bwt) co-administered with PB (63 mg/kg bwt)."( Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses.
Alvarez, LI; Fiel, C; Fusé, LA; Lanusse, CE; McKellar, QA; Moreno, L; Sánchez Bruni, SF; Saumell, CA, 2005
)
0.56
" Small-scale field trials showed excellent levels of pyrethroid control when insects were pretreated with PBO and then dosed with pyrethroid during the time of maximum esterase inhibition."( Effect of pretreatment with piperonyl butoxide on pyrethroid efficacy against insecticide-resistant Helicoverpa armigera (Lepidoptera: Noctuidae) and Bemisia tabaci (Sternorrhyncha: Aleyrodidae).
Gunning, RV; Moores, GD; Young, SJ, 2006
)
0.63
" The permethrin susceptibility of larvae was determined by a dose-response bioassay."( Enzymes-based resistant mechanism in pyrethroid resistant and susceptible Aedes aegypti strains from northern Thailand.
Lumjuan, N; Prapanthadara, LA; Somboon, P; Somwang, P; Suwan, W; Walton, C; Yanola, J, 2011
)
0.37
" Maternal body weight decrease and food reductions occurred over the dosing period in the 500 and 1000 mg/kg/day groups."( Developmental and reproduction toxicity of piperonyl butoxide part 1 developmental safety of piperonyl butoxide in the CD® (Sprague Dawley) rat.
Hauswirth, JW; Hoberman, AM, 2022
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Pet Supplies1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Four Paws Healthy Promise Aloe Ear Mite Treatment for Dogs -- 0.75 fl ozFour PawsPet Suppliespiperonyl butoxide, Pyrethrins2024-11-29 10:47:42

Roles (1)

RoleDescription
pesticide synergistA substance that increases the efficacy of a pesticide.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency13.80290.002541.796015,848.9004AID1347399
pregnane X receptorRattus norvegicus (Norway rat)Potency44.66840.025127.9203501.1870AID651751
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency5.56073.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency21.95490.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency55.93330.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency2.60300.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.14820.000221.22318,912.5098AID1259243; AID743035; AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency10.00000.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency37.40900.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency10.12900.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency22.98610.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.06660.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency36.74370.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency69.88810.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.86960.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency36.80910.001530.607315,848.9004AID1224841; AID1224848; AID1224849
farnesoid X nuclear receptorHomo sapiens (human)Potency55.75970.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency16.94410.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency36.25230.000229.305416,493.5996AID1259244; AID743069; AID743075
GVesicular stomatitis virusPotency0.12540.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency1.27200.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency50.11870.001024.504861.6448AID588535
aryl hydrocarbon receptorHomo sapiens (human)Potency21.00390.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency69.42750.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency20.85410.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency22.13760.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.248419.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency55.60710.057821.109761.2679AID1159526
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency31.62280.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency36.68910.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency49.15090.000627.21521,122.0200AID743202
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.50120.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency31.01210.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.12540.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.12540.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency34.79620.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency31.01210.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency23.71010.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.12540.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.12540.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (199)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (60)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1110846Resistance ratio of LC50 for Tetranychus urticae SR-VP (two-spotted spider mite) larvae reared under continuous pressure of 5000 mg/L spirodiclofen for 5 months in presence of 200 mg/L cytochrome P450 monooxygenase inhibitor, PBO to LC50 for Tetranychus u2009Pest management science, Apr, Volume: 65, Issue:4
Genetic and biochemical analysis of a laboratory-selected spirodiclofen-resistant strain of Tetranychus urticae Koch (Acari: Tetranychidae).
AID1110836Non-competitive inhibition of B-type Bemisia tabaci (sweet potato whitefly) esterase using 1-naphthyl butyrate as substrate after 10 to 120 min2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID1110833Inhibition of B-type Bemisia tabaci (sweet potato whitefly) oxidase-mediated O-deethylation using 285 uM of 7-ethoxycoumarin as substrate assessed as residual activity after 10 min relative to control2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1111932Inhibition of Frankliniella occidentalis ACR (western flower thrips) total esterase activity2011Pest management science, Dec, Volume: 67, Issue:12
Esterase inhibition by synergists in the western flower thrips Frankliniella occidentalis.
AID1111931Inhibition of Frankliniella occidentalis MET (western flower thrips) total esterase activity2011Pest management science, Dec, Volume: 67, Issue:12
Esterase inhibition by synergists in the western flower thrips Frankliniella occidentalis.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1110832Inhibition of B-type Bemisia tabaci (sweet potato whitefly) oxidase-mediated O-deethylation using 285 uM of 7-ethoxycoumarin as substrate assessed as residual activity after 120 min relative to control2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID1110835Inhibition of B-type Bemisia tabaci (sweet potato whitefly) esterase using 31.25 uM of 1-naphthyl butyrate as substrate after 120 min2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID1111934Inhibition of Frankliniella occidentalis MLFOM (western flower thrips) total esterase activity2011Pest management science, Dec, Volume: 67, Issue:12
Esterase inhibition by synergists in the western flower thrips Frankliniella occidentalis.
AID1110837Inhibition of B-type Bemisia tabaci (sweet potato whitefly) esterase using 500 uM of 1-naphthyl butyrate as substrate after 120 min2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID1150146Inhibition of aniline hydroxylase activity of mixed function oxidase system in Wistar rat liver microsomes assessed as conversion of aniline to p-aminophenol after 10 mins1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Inhibitors of hepatic mixed function oxidase. 3. Inhibition of hepatic microsomal aniline hydroxylase and aminopyrine demethylase by 2,6- and 2,4-dihydroxyphenyl alkyl ketones and related compounds.
AID1111933Inhibition of Frankliniella occidentalis FOR (western flower thrips) total esterase activity2011Pest management science, Dec, Volume: 67, Issue:12
Esterase inhibition by synergists in the western flower thrips Frankliniella occidentalis.
AID1110838Inhibition of B-type Bemisia tabaci (sweet potato whitefly) esterase using 500 uM of 1-naphthyl butyrate as substrate after 10 min2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID1110831Inhibition of B-type Bemisia tabaci (sweet potato whitefly) oxidase-mediated O-deethylation using 18 uM of 7-ethoxycoumarin as substrate assessed as residual activity after 10 min relative to control2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1110834Reversible inhibition of B-type Bemisia tabaci (sweet potato whitefly) esterase using 1-naphthyl butyrate as substrate after 10 to 120 min2009Pest management science, Feb, Volume: 65, Issue:2
An analogue of piperonyl butoxide facilitates the characterisation of metabolic resistance.
AID1110858Insecticidal activity against Tetranychus urticae LS-VL (two-spotted spider mite) larvae reared under continuous pressure of 5000 mg/L spirodiclofen for 5 months assessed as mortality treated 3-4 hr after 200 mg/L cytochrome P450 monooxygenase inhibitor, 2009Pest management science, Apr, Volume: 65, Issue:4
Genetic and biochemical analysis of a laboratory-selected spirodiclofen-resistant strain of Tetranychus urticae Koch (Acari: Tetranychidae).
AID1110855Synergism factor, ratio of LC50 for Tetranychus urticae LS-VL (two-spotted spider mite) larvae to LC50 for Tetranychus urticae LS-VL larvae in presence of 200 mg/L cytochrome P450 monooxygenase inhibitor, PBO2009Pest management science, Apr, Volume: 65, Issue:4
Genetic and biochemical analysis of a laboratory-selected spirodiclofen-resistant strain of Tetranychus urticae Koch (Acari: Tetranychidae).
AID1150147Inhibition of aminopyrine demethylase activity of mixed function oxidase system in Wistar rat liver microsomes assessed as conversion of aminopyrine to 4-aminoantipyrine after 20 mins1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Inhibitors of hepatic mixed function oxidase. 3. Inhibition of hepatic microsomal aniline hydroxylase and aminopyrine demethylase by 2,6- and 2,4-dihydroxyphenyl alkyl ketones and related compounds.
AID1112786Insecticidal activity against Frankliniella occidentalis R1S (western flower thrips) in compound treated sweet pepper leaf assessed as mortality at 1000 mg/l at 25 +/- 2 degC by leaf dip method2013Pest management science, Feb, Volume: 69, Issue:2
Thiamethoxam acts as a target-site synergist of spinosad in resistant strains of Frankliniella occidentalis.
AID1110852Insecticidal activity against Tetranychus urticae SR-VP (two-spotted spider mite) larvae reared under continuous pressure of 5000 mg/L spirodiclofen for 5 months assessed as mortality treated 3-4 hr after 200 mg/L cytochrome P450 monooxygenase inhibitor, 2009Pest management science, Apr, Volume: 65, Issue:4
Genetic and biochemical analysis of a laboratory-selected spirodiclofen-resistant strain of Tetranychus urticae Koch (Acari: Tetranychidae).
AID1110849Synergism factor, ratio of LC50 for Tetranychus urticae SR-VP (two-spotted spider mite) larvae to LC50 for Tetranychus urticae SR-VP larvae in presence of 200 mg/L cytochrome P450 monooxygenase inhibitor, PBO2009Pest management science, Apr, Volume: 65, Issue:4
Genetic and biochemical analysis of a laboratory-selected spirodiclofen-resistant strain of Tetranychus urticae Koch (Acari: Tetranychidae).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (795)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990210 (26.42)18.7374
1990's121 (15.22)18.2507
2000's166 (20.88)29.6817
2010's215 (27.04)24.3611
2020's83 (10.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.54 (24.57)
Research Supply Index6.76 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index114.37 (26.88)
Search Engine Supply Index3.09 (0.95)

This Compound (45.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (3.48%)5.53%
Reviews16 (1.92%)6.00%
Case Studies9 (1.08%)4.05%
Observational1 (0.12%)0.25%
Other778 (93.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]